REG - Oncimmune Hldgs PLC - Appointment of Non-Executive Director

Oncimmune HoldingsAnnouncement

13/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230113:nRSM5860Ma&default-theme=true

RNS Number : 5860M  Oncimmune Holdings PLC  13 January 2023

13 January 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Appointment of Non-Executive Director

 

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group,
is pleased to announce that further to the announcement made on 7 December
2022, John Goold has been appointed to the Board of the Company as
Non-Executive Director with immediate effect, following the successful
completion of customary due diligence checks by the Company's Nominated
Adviser.

 

Additional Information in respect of the AIM Rules

The following information regarding the appointment of John Howard Goold, aged
51, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 Current Directorships      Previous Directorships (within the last five years)
 Freelands Finance Limited  Zeus Capital Limited

 Kelso Group Holdings plc   Zeus Group Limited

 Kelso Ltd                  Zeus Securities Limited

                            Zeus Capital Investment Limited

As at the date of this announcement, John Goold holds 1,150,000 ordinary
shares in the Company equivalent to 1.55% of the Company's issued share
capital.

Save as set out above there are no further disclosures pursuant to Rule 17 or
Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the
appointment of John Goold.

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser, Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT®, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT® Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDBCGBDGXD